The US Oncology Network

As a leader in cancer research, we believe in making clinical trials more widely available to help in the fight against cancer. That's why we're excited about the BRUIN CLL-321 trial, which is the first randomized phase III study to evaluate outcomes in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after treatment with covalent BTK inhibitors. The trial's findings were presented at #ASH24 by Jeff Sharman M.D., Director of Research at the Willamette Valley Cancer Institute & Research Center and Medical Director of Hematology Research at the Sarah Cannon Research Institute. These results offer promising potential for a tolerable, non-chemotherapy option for high-risk CLL and SLL patients. Find out more about Dr. Sharman's research here: https://lnkd.in/gt-Wu8UA #ClinicalTrials #CancerCare #Leukemia

We were excited to see Debra Patt, MD PhD MBA?sharing her expertise at SXSW regarding the promising future of personalized cancer care! Her discussion with Troy C. Sarich, Ph.D. of Johnson & Johnson touched on the need for investments in technology like clinical decision support and AI to make care more accessible and affordable. At The Network, our goal is to make that kind of care available to patients close to home. Listen to the full recording here: https://lnkd.in/gFbQkiwC and find out more about the SXSW presentation below. #PersonalizedCare #SXSW2025 #HealthcareInnovation

We're thrilled to share results from the first performance period (PP1) of the Centers for Medicare & Medicaid Services?(CMS)?Enhancing Oncology Model (EOM). The 12 practices in The Network participating in EOM PP1 achieved a remarkable?$44 million in gross savings?for Medicare—while delivering exceptional, high-quality care to EOM patients. ? This early success is a testament to the dedication and expertise of the participating practices. As we continue to innovate and strive for excellence in oncology care, we're encouraged by the positive impact this will have on patient outcomes and healthcare efficiency. ? Together, we're not just meeting benchmarks; we're setting new standards. #Medicare #CommunityOncology #EOM

We're excited to see these positive results from an important clinical trial showing that the immunotherapeutic agent galinpepimut-S (GPS) demonstrated signals of efficacy and specific T-Cell immune responses. The trial also showed a median survival of 13.5 months for patients with acute myeloid leukemia (AML) in remission, compared to six months for conventional therapy. According to Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center, “The interim results represent a major step forward in the treatment of AML, offering hope for patients in remission." Find out more about the study here: https://lnkd.in/dTmzfj9R #ClinicalTrials #Leukemia #CancerCare

We believe in making cutting-edge technology and treatments available to more patients and providers. That's why we're excited to see this write-up from #ASH24, where Dr. Ira Zackon, hematologist with New York Oncology Hematology and Senior Medical Director with Ontada, talks about the results of a recent study on the use of bispecific antibodies in adult patients with relapsed/refractory multiple myeloma. Studies like this could lead to more real-world applications for important treatments. Find out more here: https://lnkd.in/gpadFq5J #Bispecifics #CommunityOncology #ClinicalTrials

We are committed to making cutting-edge research and patient-centered care more accessible in community oncology settings. Stories like Melinda Reubens’s inspire us to keep pushing the boundaries of what’s possible in lung cancer treatment. When Melinda was diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC) nearly two years ago, treatment options were limited beyond chemotherapy. Now, thanks to advancements in clinical trials and targeted therapies, her treatment plan has expanded—providing her with new hope and a personalized approach to care. With the support of a coordinated care team at Virginia Cancer Specialists, P.C., Melinda is receiving multidisciplinary care designed to help her navigate her diagnosis with confidence. In this article from Cancer Network, Melinda and her husband Justin sit down with Alex Spira, MD, PhD, FACP, FASCO, Co-director of the Virginia Cancer Specialists Research Institute, and Julia Lazo, RN, a nurse navigator at the Research Institute, to talk about their experiences with clinical trials, side effects, and their supportive, multidisciplinary care team. Read more here: https://lnkd.in/gtDFa9pE #ClinicalTrials #NSCLC #PatientCenteredCare

It's vital that we make clinical trials as diverse as possible so that our takeaways are relevant for a broader range of patients. This important study, shared by Minnesota Oncology, has more on how we can work together to encourage community engagement and retain underrepresented groups in clinical trials moving forward. #DiversityInTrials #CancerResearch #ClinicalTrials

We are dedicated to helping community oncology practices provide the most advanced cancer care possible. We're proud that physicians in The Network are at the cutting edge of research designed to win the fight against cancer. One example is the work of Robert Rifkin, MD, FACP, medical oncologist and hematologist at Rocky Mountain Cancer Centers. Dr. Rifkin's latest study on prophylactic tocilizumab shows its potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies. This could be a game-changer for patients with relapsed/refractory?multiple myeloma, decreasing the risk of adverse events and making these therapies easier to administer in an outpatient community setting. Find out more about the study and future research in this AJMC - The American Journal of Managed Care article: https://lnkd.in/gkZnP9zb #Myeloma #CancerResearch #CommunityOncology

Devon Dickey Womack's visionary leadership in oncology care has earned her the distinguished honor of being named a Trailblazing Woman in Healthcare by Reuters Events. Through her work with The US Oncology Network, she has significantly advanced patient care while championing our I2CARE and ILEAD values. Devon's dedication inspires female leaders and drives substantial professional growth within the healthcare industry. Discover more about her remarkable contributions and achievements here: https://bit.ly/4bFZiRU

Even if you know your patients would benefit from clinical trials, it can be hard to find the right options in your local community. As a national leader in cancer research, The Network is proud to partner with the Sarah Cannon Research Institute (SCRI) to connect practices with some of the most advanced clinical trials available today. So far, we've helped over 1,300 providers at more than 250 locations across the US gain access to clinical research studies. Find out more here: https://lnkd.in/gDKYBipQ #ClinicalTrials #CancerResearch #CommunityOncology